Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Average Recommendation of “Moderate Buy” from Analysts

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $13.80.

OBIO has been the subject of several research analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research note on Thursday, November 13th. Barclays lifted their target price on shares of Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th. Finally, TD Cowen initiated coverage on shares of Orchestra BioMed in a research report on Wednesday, December 10th. They issued a “buy” rating for the company.

Orchestra BioMed Stock Performance

Shares of OBIO stock opened at $4.38 on Friday. Orchestra BioMed has a 12-month low of $2.20 and a 12-month high of $5.42. The business’s fifty day simple moving average is $4.15 and its 200-day simple moving average is $3.72. The company has a current ratio of 4.73, a quick ratio of 4.72 and a debt-to-equity ratio of 0.32. The company has a market cap of $247.34 million, a PE ratio of -2.41 and a beta of 0.61.

Institutional Trading of Orchestra BioMed

Several institutional investors have recently made changes to their positions in OBIO. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Orchestra BioMed in the 2nd quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. acquired a new stake in Orchestra BioMed in the 4th quarter valued at approximately $38,000. Creative Planning purchased a new stake in Orchestra BioMed in the second quarter valued at approximately $40,000. XTX Topco Ltd acquired a new position in Orchestra BioMed during the second quarter worth $45,000. Finally, Jane Street Group LLC acquired a new position in Orchestra BioMed during the second quarter worth $50,000. Hedge funds and other institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.